The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
UNITY BIOTECHNOLOGY, INC. COM 91381U200 3,970 10,048,181 SH   SOLE   0 0 10,048,181
DENALI THERAPEUTICS, INC. COM 24823R105 112,594 3,668,749 SH   SOLE   0 0 3,668,749
METACRINE, INC. COM 59101E103 1,426 2,940,503 SH   SOLE   0 0 2,940,503
KARUNA THERAPEUTICS, INC. COM 48576A100 295,304 1,312,872 SH   SOLE   0 0 1,312,872
RUBIUS THERAPEUTICS, INC. COM 78116T103 152 349,908 SH   SOLE   0 0 349,908
SINGULAR GENOMICS SYSTEMS, INC. COM 82933R100 9,497 3,798,926 SH   SOLE   0 0 3,798,926
EQRX, INC. COM 26886C107 179,860 36,335,375 SH   SOLE   0 0 36,335,375
ERASCA, INC. COM 29479A108 86,233 11,055,554 SH   SOLE   0 0 11,055,554
VERVE THERAPEUTICS, INC. COM 92539P101 69,003 2,008,809 SH   SOLE   0 0 2,008,809
REVOLUTION HEALTHCARE ACQUISITION CORP. COM 76155Y108 13,342 1,357,237 SH   SOLE   0 0 1,357,237